FDA Approves First Daily Pill for Weight Loss Treatment
The FDA approved the first daily oral GLP-1 drug for weight management, showing about 16.6% average weight loss in trials, expanding options beyond injections.
- On Dec. 22, 2025 the U.S. Food and Drug Administration approved a pill version of Wegovy, Novo Nordisk A/S's first oral GLP-1 therapy cleared for weight management in the United States.
- In the 64-week OASIS 4 trial, 307 adult participants randomized to oral semaglutide 25 mg showed mean weight loss of about 17% when treatment was adhered to.
- Among trial participants, 76% achieved at least 5% weight loss; a 1.5 mg starting dose will be available in early January for $149 per month, and production is underway at Novo Nordisk North Carolina manufacturing sites.
- Novo Nordisk plans a U.S. launch in early January 2026, including an indication to reduce major adverse cardiovascular events, while pricing and demand remain key market factors.
- Facing competition from Eli Lilly, Novo Nordisk struggles to regain share as more patients choose Zepbound, while it argues a convenient GLP-1 pill without cold storage could boost interest but unclear if market share will rise.
381 Articles
381 Articles
First GLP-1 weight-loss pill on sale in the US within weeks for $149 a month
The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving Novo Nordisk's highly anticipated oral GLP-1 drug – with a starting dose available in early January for US$149.Continue ReadingCategory: Obesity, Illnesses and conditions, Body and MindTags: Novo Nordisk, Eli Lilly, Ozempic, clinical trials, FDA, Obesity, Weight Loss
FDA approves pill version of Wegovy
(CNN)– People who are severely overweight will soon have a new option to help them shed unwanted pounds. The Food and Drug Administration (FDA) has approved a daily pill of the weight loss drug Wegovy. Currently, patients must get weekly injections of the drug. The pill’s maker, Novo Nordisk said the pill version had about the same weight loss and side effects in clinical trials as the Wegovy shot. The company’s lead doctor said the FDA’s decisi…
Weight loss drugs battle Kentucky's obesity epidemic
The Food and Drug Administration's approval of a Wegovy pill, the first ever oral GLP-1 medication on Dec. 22, underscores an increasing demand for weight loss drugs across the U.S. and Kentucky.
Wegovy is coming in pill form. Here’s when, how much, and how well it works
People who are squeamish about needles will soon have an alternative, as the Food and Drug Administration has approved a pill version of Wegovy that could be available as soon as next month. Novo Nordisk, maker of the GLP-1 weight-loss drug, announced on Monday that it has received FDA approval for its once-daily pill that has been shown to achieve comparable weight-loss results as the injectable Wegovy. The Danish drugmaker said the pill could …
Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss
Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January. The post Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss appeared first on MedCity News.
Coverage Details
Bias Distribution
- 65% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
































